A case study in dual quantification of CAR-T and tumor DNA in mixed human-mouse tissues.
Introduction
Cell and Gene Therapy programs require bioanalytical methods capable of detecting low-copy targets in complex matrices, distinguishing therapeutic signal from host genomic background, and supporting biodistribution and persistence decisions with confidence. Digital PCR (dPCR) addresses these needs by partitioning a bulk PCR reaction into thousands of smaller reactions and enabling absolute endpoint quantification without dependence on a standard curve [1,2].
This white paper presents an internal Noble Life Sciences case study to describe how dPCR can track both an engineered immune effector population and tumor burden within the same preclinical model. The dataset focuses on anti-CD19 CAR-T cells and NALM6 leukemic cells in NOD scid gamma (NSG) mice, while the broader analytical principles are relevant to Cell and Gene Therapy workflows that require multiplexed quantification in mixed-species tissues [3-9].

Why dPCR matters for Cell and Gene Therapies
PCR-based methods, including qPCR and dPCR, are the preferred and dominant quantitative platform in Cell and Gene Therapy bioanalysis, supporting biodistribution, vector shedding, transgene detection, and cellular-kinetic studies. dPCR adds value for low-abundance targets in complex or mixed-genomic matrices because it provides sensitive, reproducible, absolute quantification without a calibration curve [5,8,9]. In adoptive cell therapy programs, PCR-based methods complement flow cytometry and imaging by tracking transgene-bearing cells in blood and tissues over time [3-6].
Figure 1. Study Design Diagram. Untreated animals received tumor cells only, whereas treated animals received tumor cells followed by anti-CD19 CAR-T cell administration prior to tissue collection.
Improving Partition Quality Before Endpoing Calling
In tissue biodistribution studies, assay chemistry is only part of the story. Sample preparation can materially affect partition behavior, signal separation, and confidence in threshold setting. Long, high-molecular-weight DNA can distribute unevenly across partitions, broadening positive clusters and increasing partition-to-partition variability.
In the case study, EcoRI digestion produced a noticeably tighter positive population than the undigested condition and reduced the V-shaped pattern seen in the one-dimensional fluorescence plots. For mixed-species studies, this front-end optimization is important because cleaner partition behavior improves calling robustness before downstream interpretation of biodistribution or persistence trends.
Figure 2. Fluorescence scatterplots. EcoRI digestion improved partition uniformity and positive-cluster separation relative to undigested DNA.
Analytical Performance: Duplexing Preserved Quantitative Response
Performance was evaluated from 0.1 to 400 ng and is reported over 0.2 to 400 ng, because the 0.1-ng data point was detectable but did not meet the quantitative precision criterion. Across the plotted range, both target assays retained a near-linear response in the single-color and duplex-color formats, with log-log fits producing R² values of 0.9995 or higher for every plotted line. Using %CV ≤ 25% across triplicate reactions, the practical LLOQ for both formats is approximately 30 copies, while approximately 15 copies can be detected but should not be reported as quantitatively reliable.
Note: Copy numbers are reported as mean copies per reaction across triplicate reactions. LLOQ is based on triplicate precision of %CV ≤ 25%. Approximately 15-copy signals exceeded this threshold and are treated as detected, not quantified.
Figure 3. Assay performance comparison between single-color and duplex-color dPCR formats. Data are plotted across 0.2-400 ng, excluding the 0.1-ng point. The y-axis reports mean copies across triplicate reactions. Both axes use a log scale; R² values for the log-log fits are shown in the panel legends. The lowest plotted level corresponds to approximately 30 mean copies per reaction, consistent with the %CV ≤ 25% LLOQ criterion.
Biodistribution Findings In Treated Versus Untreated Animals
When applied to tissue-derived DNA rather than purified cell-line DNA, the duplex assay continued to distinguish tumor-associated and CAR-T-associated signals in the same reaction, remaining interpretable in a biologically complex matrix and generating parallel tissue-level readouts for both cell populations.
Figure 4. Biodistribution of tumor and CAR-T DNA across eight tissues. DNA isolated from eight tissues harvested from untreated, tumor-bearing mice and CAR-T-treated, tumor-bearing mice was analyzed in triplicate by dPCR. For each mouse, tumor and/or CAR-T DNA copy numbers were averaged across triplicate reactions. Tissue-level values were then averaged across two mice per group (n = 2) and are expressed as mean copies per 1 µg of tissue DNA. Error bars represent standard deviation (SD).
In this pilot dataset, tumor-associated signal was highest in the spleen in both groups. Outside the spleen, treated animals generally had lower tumor-associated signal than untreated controls, while CAR-T-associated FLAG signal was detectable in several treated-animal tissues, most notably in the liver and lung. Because the group size was small, these findings should be interpreted as an assay-utility demonstration rather than a definitive efficacy or tissue-tropism conclusion.
How Noble Can Apply dPCR Across Cell and Gene Therapy Programs
As a preclinical contract research organization (CRO) with both GLP and non-GLP laboratory capabilities, Noble Life Sciences offers dPCR services that can be configured around sponsor-specific targets, matrices, and development questions. Noble provides support for customized assay design, target selection, high-throughput execution, and data analysis across Cell and Gene Therapy, copy-number analysis, rare mutation detection, and residual DNA quantification [10,11]. The QIAcuity integrated workflow supports rapid preclinical decision cycles.
Conclusion
For Cell and Gene Therapy developers, the key success criterion is an assay that resolves biologically meaningful signals in a real development program. In this case study, Noble’s duplex-color dPCR approach distinguished tumor and CAR-T DNA in mixed human-mouse tissues, supported an LLOQ of approximately 30 copies using %CV ≤ 25%, detected lower signals near 15 copies without reporting them as quantitative, and preserved quantitative performance when two targets were combined in a single reaction. Together, these attributes make dPCR a practical option for preclinical biodistribution, persistence, and translational decision-making across Cell and Gene Therapy programs.
Noble Life Sciences supports digital PCR (dPCR) for cell and gene therapy programs, providing sensitive, absolute quantification for biodistribution, persistence, and other low-copy applications. Our dPCR capabilities support single-target and duplex quantification in complex tissue matrices, with customized assay design and workflows aligned to sponsor-specific development questions. Contact us through our website at noblelifesci.com.
Selected References and Online Sources
[1] Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Analytical Chemistry. 2011;83(22):8604-8610. https://doi.org/10.1021/ac202028g
[2] Huggett JF, Foy CA, Benes V, et al. The Digital MIQE Guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments. Clinical Chemistry. 2013;59(6):892-902. https://doi.org/10.1373/clinchem.2013.206375
[3] June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-1365. https://doi.org/10.1126/science.aar6711
[4] Mhaidly R, Verhoeyen E. Humanized mice are precious tools for preclinical evaluation of CAR T and CAR NK cell therapies. Cancers. 2020;12(7):1915. https://doi.org/10.3390/cancers12071915
[5] Sugimoto H, Chen S, Minembe J-P, et al. Insights on droplet digital PCR-based cellular kinetics and biodistribution assay support for CAR-T cell therapy. The AAPS Journal. 2021;23:36. https://doi.org/10.1208/s12248-021-00560-6
[6] Lou Y, Chen C, Long X, et al. Detection and quantification of chimeric antigen receptor transgene copy number by droplet digital PCR versus real-time PCR. The Journal of Molecular Diagnostics. 2020;22(5):699-707. https://doi.org/10.1016/j.jmoldx.2020.02.007
[7] Rodgers BD, Herring SK, Carias DR, Chen J, Rocha AG. Development and validation of a model gene therapy biodistribution assay for AVGN7 using digital droplet polymerase chain reaction. Molecular Therapy – Methods & Clinical Development. 2023;29:494-503. https://doi.org/10.1016/j.omtm.2023.05.007
[8] Hays A, Wissel M, Colletti K, et al. Recommendations for method development and validation of qPCR and dPCR assays in support of cell and gene therapy drug development. The AAPS Journal. 2024;26:24. https://doi.org/10.1208/s12248-023-00880-9
[9] Fujita E, Yamamoto S, Hanada T, et al. Using qPCR and ddPCR to study biodistribution of cell therapy products: a multi-site evaluation. Cytotherapy. 2025;27(1):51-65. https://doi.org/10.1016/j.jcyt.2024.09.003
[10] QIAGEN. QIAcuity Digital PCR System. https://www.qiagen.com/us/products/instruments-and-automation/pcr-instruments/qiacuity-digital-pcr-system Accessed May 4, 2026.
[11] Noble Life Sciences. Digital PCR Services. https://noblelifesci.com/dpcr-services/ Accessed May 4, 2026.







